Systemic inflammatory response syndrome

British Journal of Surgery

Volumn 84, Issue 7, 1997, Pages 920-935

  Davies, M G ^a   Hagen, P O ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARACHIDONIC ACID DERIVATIVE; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

DRUG RESEARCH; ENDOTHELIUM CELL; HUMAN; IMMUNOPATHOGENESIS; INFLAMMATORY DISEASE; LEUKOCYTE; NONHUMAN; NUTRITION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; SYNDROME;

ARACHIDONIC ACID; CYTOKINES; ENDOTHELIUM; ENTERAL NUTRITION; HUMANS; LEUKOCYTES; NITRIC OXIDE; PLATELET ACTIVATING FACTOR; REACTIVE OXYGEN SPECIES; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

EID: 0030805693     PISSN: 00071323     EISSN: None     Source Type: Journal    
DOI: 10.1002/bjs.1800840707     Document Type: Review

References (165)

1. Parker MM, Parrillo JE. Septic shock. Hemodynamics and pathogenesis. JAMA 1983; 250: 3324-7.
2. Bone RC, Balk RA, Cerra FB et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992; 101: 1644-55.
3. Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA 1995; 273: 117-23.
4. Salvo I, de Cian W, Musicco M et al. The Italian SEPSIS study: preliminary results on the incidence and evolution of SIRS, sepsis, severe sepsis and septic shock. Intensive Care Med 1995; 21(Suppl 2): S244-9.
5. Pittet D, Rangel-Frausto S, Li N et al. Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients. Intensive Care Med 1995; 21: 302-9.
6. Smail N, Messiah A, Edouard A et al. Role of systemic inflammatory response syndrome and infection in the occurrence of early multiple organ dysfunction syndrome following severe trauma. Intensive Care Med 1995; 21: 813-16.
7. Baker CC, Huynh T. Sepsis in the critically ill patient. Curr Probl Surg 1995; 32: 1015-92.
8. Collins FM. Cellular antimicrobial immunity. CRC Critical Review in Microbiology 1978; 7: 27-91.
9. Dantzker D. Oxygen delivery and utilization in sepsis. Crit Care Clin 1989; 5: 81-98.
10. Dantzker DR, Foresman B, Gutierrez G. Oxygen supply and utilization relationships. A reevaluation. American Review Respiratory Diseases 1991; 143: 675-9.
11. Tuchschmidt J, Fried J, Astiz M, Rackow E. Elevation of cardiac output and oxygen delivery improves outcomes in septic shock. Chest 1992; 102: 216-20.
12. Slotman GJ, Burchard KW, Williams JJ, D'Arezzo A, Yellin SA. Interaction of prostaglandins, activated complement, and granulocytes in clinical sepsis and hypotension. Surgery 1986; 99: 744-51.
13. Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response system: what we do and do not know about cytokine regulation. Crit Care Med 1996; 24: 163-72.
14. Quezado ZM, Natanson C. Systemic hemodynamic abnormalities and vasopressor therapy in sepsis and septic shock. Am J Kidney Dis 1992; 20: 214-22.
15. Suffredini AF, Shelhamer JH, Neumann RD, Brenner M, Baltaro RJ, Parrillo JE. Pulmonary and oxygen transport effects of intravenously administered endotoxin in normal humans. American Review Respiratory Diseases 1992; 145: 1398-403.
16. Hinshaw LB. Sepsis/septic shock: participation of the microcirculation: an abbreviated review. Crit Care Med 1996; 24: 1072-8.
17. Graves DT, Jiang Y. Chemokines: a family of chemotactic cytokines. Crit Rev Oral BM Med 1995; 6: 109-18.
18. Van der Poll T, Buller HR, ten Cate H et al. Activation of coagulation after administration of tumor necrosis factor to normal subjects. N Engl J Med 1990; 322: 1622-7.
19. 2 in sepsis: studies in nonhuman primates after interleukin-1α administration and during lethal bacteremia. Blood 1995; 86: 1027-34.
20. Kalter ES, van Dijk WC, Timmerman A, Verhoef J, Bouma BN. Activation of purified human plasma prekallikrein trigggered by cell wall fractions of Escherichia coli and Staphylococcus aureus. J Infect Dis 1983; 148: 682-91.
21. Warr TA, Mohan Rao LV, Rapaport SI. Disseminated intravasacular coagulation in rabbits induced by administration of endotoxin or tissue factor: effect of anti-tissue factor antibodies and measurement of plasma extrinsic pathway inhibitor activity. Blood 1990; 75: 1481-9.
22. Suffredini AF, Harpel PC, Parrillo JE. Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. N Engl J Med 1989; 320: 1165-72.
23. Gando S, Kameue T, Nanzaki S, Nakanishi Y. Cytokines, soluble thrombomodulin and disseminated intravascular coagulation in patients with systemic inflammatory response syndrome. Thromb Res 1995; 80: 519-26.
24. Fourrier F, Chopin C, Goudemand J et al. Septic shock, multiple organ failure, and disseminated intravascular coagulation. Compared patterns of antithrombin III, protein C, and protein S deficiencies. Chest 1992; 101: 816-23.
25. Gando S, Kameue T, Nanzaki S, Nakanishi Y. Disseminated intravascular coagulation is a frequent complication of systemic inflammatory response syndrome. Thromb Haemost 1996; 75: 224-8.
26. Souba WW. Cytokine control of nutrition and metabolism in critical illness. Curr Probl Surg 1994; 31: 577-643.
27. Munchie HR, Manogue KR, Spriggs DR et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988; 318: 1481-6.
28. Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T. The complex pattern of cytokines in serum with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 1989; 169: 333-8.
29. Pinsky MR, Vincent JL, Deviere J, Alegre M, Kahn RJ, Dupont E. Serum cytokine levels in human septic shock. Relation to multiple-system organ failure and mortality. Chest 1993; 103: 565-75.
30. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987: i: 355-7.
31. Tracey KJ, Fong Y, Hesse DG et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 1987; 330: 662-4.
32. Suffredini AF, Fromm RE, Parker MM et al. The cardiovascular response of normal humans to the administration of endotoxin. N EnglJ Med 1989; 321: 280-7.
33. Goldie AS, Fearon KC, Ross JA et al. Natural cytokine antagonists and endogenous antiendotoxin core antibodies in sepsis syndrome. The Sepsis Intervention Group. JAMA 1995; 274: 172-7.
34. Hack CE, Nuijens JH, Felt-Bersma RJF et al. Elevated plasma levels of the anaphylatoxins C3a and C4a are associated with a fatal outcome in sepsis. Am J Med 1989; 86: 20-6.
35. Ognibene FP, Parker MM, Burch-Whitman C et al. Neutrophil aggregation activity and septic shock in humans: neutrophil aggregation by a C5a-like material occurs more frequently than complement component depletion and correlates with depression of systemic vascular resistance Journal of Critical Care 1988; 3: 103-11.
36. Slotman GJ, Burchard KW, Williams JJ, DiArezzo A, Yellin SA. Interaction of prostaglandins, activated complement, and granulocytes in clinical sepsis and hypotension. Surgery 1986; 99; 744-51.
37. Pixley RA, Zellis S, Bankes P et al. Prognostic value of assessing contact system activation and factor V in systemic inflammatory response syndrome. Crit Care Med 1995; 23: 41-51.
38. Yentis SM, Soni N, Sheldon J. C-reactive protein as an indicator of resolution of sepsis in the intensive care unit. Intensive Care Med 1995; 21: 602-5.
39. Tobias PS, Mathison JC, Ulevitch RJ. A family of lipopolysaccharide binding proteins involved in responses to Gram-negative sepsis. J Biol Chem 1988; 263: 13 479-81.
40. Tobias PS, Soldau K, Ulevitch RJ. Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum. J Exp Med 1986; 164: 777-93.
41. Schumann RR, Leong SR, Flaggs GW et al. Structure and function of lipopolysaccharide binding protein. Science 1990; 249: 1429-31.
42. Opal SM, Fisher CJ, Marra MN, Scott RW, Palardy JE, Brown U. Bactericidal/permeability-increasing protein as a novel therapeutic modality in the treatment of endotoxic shock. Clin Res 1991; 39: 351A (Abstract).
43. Parsons PE, Gillespie MK, Moore EE, Moore FA, Worthen GS. Neutrophil response to endotoxin in the adult respiratory distress syndrome: role of CD14. Am J Respir Cell Mol Biol 1995; 13: 152-60.
44. Fong Y, Moldawer LL, Shires GT, Lowry SF. The biologic characteristics of cytokines and their implication in surgical injury. Surg Gynecol Obstet 1990; 170: 363-78.
45. Tsujimoto M, Vilcek J. Tumor necrosis factor receptors in UeLa cells and their regulation by interferon-gamma. J Biol Chem 1986; 261: 5384-8.
46. Aggarwal BB, Eessalu TE, Hass PE. Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon. Nature 1985; 318: 665-7.
47. Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA. Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988; 81: 1162-72.
48. Tracey KJ, Beutler B, Lowry SF et al. Shock and tissue injury induced by recombinant human cachectin. Science 1986; 234: 470-4.
49. Beutler B, Milsark IW, Cerami A. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229: 869-71.
50. Kawakami M, Cerami A. Studies of endotoxin-induced decrease in lipoprotein lipase activity. J Exp Med 1981; 154: 631-9.
51. Dinarello CA. Interleukin-1. Reviews of Infectious Diseases 1984; 6: 51-95.
52. Pruitt JH, Copeland EMI, Moldawer LL. Interleukin-1 and interleukin-1 antagonism in sepsis, systemic inflammatory response syndrome, and septic shock. Shock 1995; 3: 235-51.
53. March CJ, Mosley B, Larsen A et al. Cloning sequence and expression of two distinct human interleukin-1 complementary DNAs. Nature 1985; 315: 641-7.
54. Giri JG, Wells J, Dower SK et al. Elevated levels of shed type II IL-1 receptor in sepsis. Potential role for type II receptor in regulation of IL-1 responses. J Immunol 1994; 153: 5802-9.
55. Fong Y, Moldawer LL, Marano M et al. Endotoxemia elicits increased circulating beta 2-IFN/IL-6 in man. J Immunol 1989; 142: 2321-4.
56. Nawroth PP, Handley DA, Esmon CT, Stern DM. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci U S A 1986; 83: 2460-4.
57. May LT, Ghrayeb J, Santhanam U et al. Synthesis and secretion of multiple forms of 'beta2 interferon/B cell differentiation factor BSF-2/hepatocyte stimulating factor' by human fibroblasts and monocytes. J Biol Chem 1989; 263: 7760-6.
58. Fong Y, Tracey KJ, Moldawer LL et al. Antibodies to cachectin/tumor necrosis factor reduce interleukin-1β and interleukin-6 appearance during lethal bacteremia. J Exp Med 1989; 170: 1627-33.
59. Starnes HF Jr, Pearce MK, Tewari A, Yim JH, Zon JC, Abrams JS. Anti-IL-6 monoclonal antibodies protect against lethal Escherichia coli infection and lethal tumor necrosis factor-α challenge in mice. J Immunol 1990; 145: 4185-91.
60. Harada A, Sekido N, Akahoshi T, Wada T, Mukaida N, Matsushima K. Essential involvement of interleukin-8 (IL-8) in acute inflammation. J Leukoc Biol 1994; 56: 559-64.
61. Davies MG, Hagen P-O. The vascular endothelium. A new horizon. Ann Surg 1993; 218: 593-609.
62. Eisenherg PR. Endothelial cell mediators of thrombosis and fibrinolysis: Review in depth. Coronary Artery Diseases 1991; 2: 129-66.
63. Ley K. Leukocyte adhesion to vascular endothelium. J Reconstr Microsurg 1992; 8: 495-503.
64. Fujishima S, Aikawa N. Neutrophil-mediated tissue injury and its modulation. Intensive Care Med 1995; 21: 277-85.
65. Rosenbloom AJ, Pinsky MR, Bryant JL, Shin A, Tran T, Whiteside T. Leukocyte activation in the peripheral blood of patients with cirrhosis of the liver and SIRS. Correlation with serum interleukin-6 levels and organ dysfunction. JAMA 1995; 274: 58-65.
66. 4 by the human neutrophil when studied in a cell superfusion model. J Immunol 1989; 143: 3659-65.
67. Bussolino F, Aglietta M, Sanavio F, Stacchini A, Lauri D, Camussi G. Alkyl-ether phosphoglycerides influence calcium fluxes into human endothelial cells. J Immunol 1985; 135: 2748-55.
68. Pereira HA. CAP37, a neutrophil-derived multifunctional inflammatory mediator. J Leukoc Biol 1995; 57: 805-12.
69. Ahmed NA, Yee J, Giannias B, Kapadia B, Christou NV. Expression of human neutrophil L-selectin during the systemic inflammatory response syndrome is partly mediated by tumor necrosis factor at. Arch Surg 1996; 131: 31-5.
70. Gawaz M, Fateh-Moghadam S, Pilz G, Gurland HJ, Werdan K. Platelet activation and interaction with leukocytes in patients with sepsis or multiple organ failure. Eur J Clin Invest 1995; 25: 843-51.
71. Haj MA, Neilly IJ, Robbie LA, Adey GD, Bennett B. Influence of white blood cells on the fibrinolytic responses to sepsis: studies of septic patients with and without severe leucopenia. Br J Haematol 1995; 90: 541-7.
72. Ridings PC, Windsor AC, Jutila MA et al. A dual-binding antibody to E and L-selectin attenuates sepsis-induced lung injury. Am J Respir Crit Care Med 1995; 152: 247-53.
73. Ridings PC, Bloomfield GL, Holloway S et al. Sepsis-induced acute lung injury is attenuated by selectin blockade following the onset of sepsis. Arch Surg 1995; 130: 1199-208.
74. Cybulsky MI, Gimbrone MA Jr. Endothelial expression of a mononuclear leukocyte adhesion molecule during atherogenesis. Science 1991; 251: 788-91.
75. Cushing SD, Fogelman AM. Monocytes may amplify their recruitment into inflammatory lesions by inducing monocyte chemotactic protein. Arteriosclerosis and Thrombosis 1992; 12: 78-82.
76. Yla-Hettuala S, Lipton BA, Rosenfeld ME et al. Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci U S A 1991; 88: 5252-6.
77. Nelken NA, Coughlin SR, Gordon D, Wilcox JN. Monocyte chemoattractant protein-1 in human atheromatous plaques. J Clin Invest 1991; 88: 1121-7.
78. Wang JM, Sica A, Peri G et al. Expression of monocyte chemotactic protein and interleukin-8 by cytokine-activated vascular smooth muscle cells. Arteriosclerosis and Thrombosis 1991; 11: 1166-74.
79. Sporn SA, Eierman DF, Johnson CE et al. Monocyte adherence results in selective induction of novel genes sharing homology with mediators of inflammation and tissue repair. J Immunol 1990; 144: 4434-41.
80. Nelson NJ, Belosevic M, Green SJ, Turpin J, Nacy CA. Interleukin-2 and the regulation of activated macrophage cytotoxic activities. Adv Exp Med Biol 1992; 319: 77-88.
81. Unanue ER, Allen PM. The basis for the immunoregulatory role of macrophages and other accessory cells. Science 1987; 236: 551-7.
82. Nussler AK, Billiar TR. Inflammation, immunoregulation, and inducible nitric oxide synthase. J Leukoc Biol 1993; 54: 171-8.
83. Wolfe TA, Dasta JF. Use of nitric oxide synthase inhibitors as a novel treatment for septic shock. Ann Pharmacother 1995; 29: 36-46.
84. Nathan CT, Hibbs JB Jr. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol 1991; 3: 65-70.
85. Thiemermann C. The role of the L-arginine-nitric oxide pathway in circulatory shock. Adv Pharmacol 1994; 28: 45-79.
86. Morris SM Jr, Billiar TR. New insights into the regulation of inducible nitric oxide synthesis. Am J Physiol 1994; 266: E829-39.
87. Brady AJ, Poole-Wilson PA. Circulatory failure in septic shock. Nitric oxide: too much of a good thing? Brit Heart J 1993; 70: 103-5.
88. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science 1992; 257: 387-9.
89. Goode HF, Howdle PD, Walker BE, Webster NR. Nitric oxide synthase activity is increased in patients with sepsis syndrome. Clin Sci 1995; 88: 131-3.
90. Nava E, Palmer RMJ, Moncada S. Inhibition of nitric oxide synthesis in septic shock: how much is beneficial. Lancet 1991; 338: 1555-7.
91. Kilbourn RG, Gross SS, Jubran A et al. N-methyl L-arginine inhibits tumor necrosis factor-induced hypotension: implications for the involvement of nitric oxide. Proc Ntl Acad Sci USA 1990; 87: 3629-32.
92. Pastor C, Teisseire B, Vicaut E, Payen D. Effects of L-arginine and L-nitro-arginine treatment on blood pressure and cardiac output in a rabbit endotoxin shock model. Crit Care Med 1994; 22: 465-9.
93. Petros A, Bennet D, Vallance P. Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock. Lancet 1991; 338: 1557-8.
94. Geroulanos S, Schilling J, Cakmakci M, Jung HH, Largiader F. Inhibition of NO synthesis in septic shock. Lancet 1992; 339: 435(Letter).
95. Hibbs JB Jr, Taintor RR, Vavrin Z, Rachlin EM. Nitric oxide: a cytotoxic activated macrophage effector molecule. Biochem Biophys Res Commun 1989; 157: 87-94.
96. Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-42.
97. Katusic ZS, Vanhoutte PM. Superoxide anion is an endothelium-derived contracting factor. Am J Physiol 1989; 257: H33-7.
98. Rubanyi GM. Vascular effects of oxygen-derived free radicals. Free Radic Biol Med 1988; 4: 107-20.
99. Haglund U, Gerdin B. Oxygen-free radicals (OFR) and circulatory shock. Circ Shock 1991; 34: 405-11.
100. Conner EM, Grisham MB. Inflammation, free radicals, and antioxidants. Nutrition 1996; 12: 274-7.
101. Lucchesi BR. Complement, neutrophils and free radicals: mediators of reperfusion injury. Arzneimittelforschung 1994; 44: 420-32.
102. Swank DW, Moore SB. Roles of the neutrophil and mediators in adult respiratory distress syndrome. Mayo Clin Proc 1989; 64: 1118-32.
103. Bernard GR. N-acetylcysteine in experimental and clinical acute lung injury. Am J Med 1991; 91: 54-9S.
104. Sun X-M, Hsueh W. Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor. J Clin Invest 1988; 81: 1328-31.
105. Touvay C, Vilain B, Carre C, Mencia-Huerta JM, Braquet P. Role of platelet-activating factor (PAF) in the bronchopulmonary alterations and beta-adrenoceptor function induced by endotoxin. Biochem Biophys Res Commun 1988; 152: 527-33.
106. Moore JM, Earnest MA, DiSimone AG, Abumrad NN, Fletcher JR. A PAF antagonist BN 52021, attenuates thromboxane release and improves survival in lethal canine endotoxemia. Circ Shock 1991; 35: 53-9.
107. Yue TL, Farhat M, Rabinovici R, Perera PY, Vogel SN, Feuerstein G. Protective effect of BN50739, a new platelet-activating factor antagonist, in endotoxin-treated rabbits. J Pharmacol Exp Ther 1990; 254: 976-81.
108. McClave SA, Lowen CC, Snider HL. Immunonutrition and enterai hyperalimentation of critically ill patients. Dig Dis Sci 1992; 37: 1153-61.
109. Ziegler TR, Gatzen C, Wilmore DW. Strategies for attenuating protein-catabolic responses in the critically ill. Annu Rev Med 1994; 45: 459-80.
110. McMahon MM, Farnell MB, Murray MJ. Nutritional support of critically ill patients. Mayo Clin Proc 1993; 68: 911-20.
111. Bower RH, Cerra FB, Bershadsky B et al. Early enterai administration of a formula (impact) supplemented with arginine, nucleotides, and fish oil in intensive care unit patients: results of a multicenter, prospective, randomized, clinical trial. Crit Care Med 1995; 23: 436-49.
112. Alexander JW. Specific nutrients and the immune response. Nutrition 1995; 11(Suppl 2): 229-32.
113. Parrillo JE. Management of septic shock: present and future. Ann Intern Med 1991; 115: 491-3.
114. Ziegler EJ, McCutchan JA, Fierer J et al. Treatment of Gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. N Engl J Med 1982; 307: 1225-30.
115. J5 Study Group. Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study. J Infect Dis 1992; 165: 695-701.
116. Calandra T, Glauser MP, Schellekens J, Verhoef J. Treatment of Gram-negative septic shock with human IgG antibody to Escherichia coli J5: a prospective, double-blind randomized trial. J Infect Dis 1988; 158: 312-19.
117. Baumgartner JD, Glauser MP, McCutchan JA et al. Prevention of Gram-negative shock and death in surgical patients by an antibody to endotoxin core glycolipid. Lancet 1985; ii: 59-63.
118. McCutchen JA, Wolf JL, Ziegler EJ. Ineffectiveness of single-dose human antiserum to core glycolipid (E. coli J5) for prophylaxis of bacteremic, Gram-negative infections in patients with prolonged neutropenia. Schweiz Med Wochenschr 1983; 113(Suppl 14): 40-5.
119. Golenbock DT, Leggett JE, Rasmussen P, Craig WA, Raetz CR, Protor RA. Lipid X protects mice against fatal Escherichia coli infection. Infect Immun 1988; 56: 779-84.
120. Chase JJ, Kubey W, Dulek MH et al. Effect of monophosphoryl lipid A on host resistance to bacterial infection. Infect Immun 1986; 53: 711-12.
121. Astiz ME, Rackow EC, Kim YB, Weil MH. Monophosphoryl lipid A induces tolerance to lethal hemodynamic effects of endotoxemia. Circ Shock 1991; 33: 92-7.
122. Nakamura H, Ishizaka A, Urano T et al. Effects of pretreatment with SDZ MRL 953, a novel imunostimulatory lipid A analog, on endotoxin-induced acute lung injury in guinea pigs. Clinical and Diagnostic Laboratory Immunology 1995; 2: 672-7.
123. Greenman RL, Schein RMH, Martin MA et al. A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of Gram-negative sepsis. The XOMA Sepsis Study Group. JAMA 1991; 266: 1097-102.
124. Bone RC, Balk RA, Fein AM et al. A second large controlled clinical study of E5, a monoclonal antibody 10 endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. Crit Care Med 1995; 23: 994-1006.
125. Ziegler EJ, Fisher CJ Jr, Sprung CL et al. Treatment of Gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind placebo-controlled trial. The HA-1A Sepsis Study Group. N Engl J Med 1991; 324: 429-36.
126. Warren HS, Danner RL, Munford RS. Anti-endotoxin monoclonal antibodies. N Engl J Med 1992; 326: 1153-7.
127. Abraham E, Wunderink R, Silverman H et al. Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-α MAb Sepsis Study Group. JAMA 1995; 273: 934-41.
128. Van Zee KJ, Kohno T, Fischer E, Rock CS, Moldawer LL, Lowry SF. Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor-α in vitro and in vivo. Proc Natl Acad Sci U S A 1992; 89: 4845-9.
129. Reinhart K, Weigand-Lohnert C, Grimminger F et al. Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study. Crit Care Med 1996; 24: 733-42.
130. Mohler KM, Torrance DS, Smith CA et al. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 1993; 151: 1548-61.
131. Fisher CJ, Agosti JM, Opal SM et al. Treatment of septic shock with the tumor necrosis factor receptor: Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. N Engl J Med 1996; 334: 1697-702.
132. Aiura K, Gelfand JA, Wakabayashi G. Interleukin-1 receptor antagonist blocks staphylococcal induced septic shock in rabbits. Cytokine 1991; 3: 498.
133. Eisenberg SP, Evans RJ, Arend WP. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature 1990; 343: 341-6.
134. Hannum CH, Wilcox CJ, Arend WP. Interleukin-1 receptor antagonist activity of a human interleukin-1 inhibitor. Nature 1990; 343: 336-40.
135. Fisher CJ Jr, Dhainaut JF, Opal SM et al. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group. JAMA 1994; 271: 1836-43.
136. Knaus WA, Harrell FE Jr, LaBrecque JF et al. Use of predicted risk of mortality to evaluate the efficacy of anticytokine therapy in sepsis. The rhIL-1ra Phase III Sepsis Syndrome Study Group. Crit Care Med 1996; 24: 46-56.
137. Bone RC, Fisher CJ Jr, Clemmer TP, Slotman GJ, Metz CA, Balk RA. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. N Engl J Med 1987; 317: 653-8.
138. The Veterans Administration Systemic Sepsis Cooperative Study Group. Effect of high-dose glucocorticoid therapy on mortality in patients with clinical signs of systemic sepsis. N Engl J Med 1987; 317: 659-65.
139. Sprung CL, Caralis PV, Marcial EH et al. The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. N Engl J Med 1984; 311: 1137-43.
140. Hinshaw LB, Beller BK, Chang ACK et al. Effects of prior administration of steroids upon recovery from lethal sepsis. Surg Gynecol Obstet 1986; 163: 335-44.
141. Taffet SM, Singhel KJ, Overholtzer JF, Shurtleff SA. Regulation of tumor necrosis factor expression in a macrophage-like cell line by lipopolysaccharide and cyclic AMP. Cell Immunol 1989; 120: 291-300.
142. Strieter RM, Remick DG, Ward PA et al. Cellular and molecular regulation of tumor necrosis factor-α production by pentoxifylline. Biochem Biophys Res Commun 1988; 155: 1230-6.
143. Schade UF. Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. Circ Shock 1990; 31: 171-81.
144. Giroir BP, Beutler B. Effect of amrinone on tumor necrosis factor production in endotoxin shock. Circ Shock 1992; 36: 200-7.
145. Graninger W, Wenisch C. Pentoxifylline in severe inflammatory response syndrome. J Cardiovasc Pharmacol 1995; 25(Suppl 2): S134-8.
146. Zeni F, Pain P, Vindimian M et al. Effects of pentoxifylline on circulating cytokine concentrations and hemodynamics in patients with septic shock: results from a double-blind, randomized, placebo-controlled study. Crit Care Med 1996; 24: 207-14.
147. Oismuller C, Mayer N, Micksche M, Steltzer H, Hammerle AF. In vitro modulation of human neutrophil function by pentoxifylline in patients with septic syndrome. Shock 1995; 4: 161-5.
148. de Felippe J, de Rocha e Silva M Jr, Marcel FMB, de Macedo Soares A, Mendes NF. Infection prevention in patients with severe multiple trauma with the immunomodulator beta 1-3 polyglucose (glucan). Surg Gynecol Obstet 1993; 177: 383-8.
149. Babineau TJ, Marcello P, Swails W, Kenler A, Bistrian B, Forse RA. Randomized Phase I/II trial of macrophage-specific immunomodulator (PGG-glucan) in high-risk surgical patients. Ann Surg 1994; 220: 601-9.
150. Willatts SM, Radford S, Leitermann M. Effect of the antiendotoxic agent, taurolidine, in the treatment of sepsis syndrome: a placebo-controlled double-blind trial. Crit Care Med 1995; 23: 1033-9.
151. Lefer AM. Significance of lipid mediators in shock states. Circ Shock 1989; 27: 3-12.
152. Harlan JM, Winn RK. The role of phospholipase products in the pathogenesis of vascular injury in sepsis. In: Root RK, Sande MA, eds. Septic Shock. Contemporary Issues in Infectious Diseases. Vol. 4. New York: Churchill Livingstone, 1985: 83-104.
153. Reines HD, Halushka PV, Cook JA, Wise WC, Rambo W. Plasma thromboxane concentrations are raised in patients dying with septic shock. Lancet 1982; ii: 174-5.
154. Kettelhut IC, Fiers W, Goldberg AL. The toxic effects of tumor necrosis factor in vivo and their prevention by cyclooxygenase inhibitors. Proc Natl Acad Sci U S A 1987; 84: 4273-7.
155. Fink MP, Morrissey PE, Stein KL, Clement RE, Fiallo V, Gardiner WM. Systemic and regional hemodynamic effects of cyclo-oxygenase and thromboxane synthetase inhibition in normal and hyperdynamic endotoxemic rabbits. Circ Shock 1988; 26: 41-57.
156. Jacobs ER, Soulsby ME, Bone RC. Ibuprofen in canine endotoxin shock. J Clin Invest 1982; 70: 536-41.
157. Haupt M, Jastremski M, Clemmer T, Metz C, Brown B. Effects of ibuprofen in patients with severe sepsis syndrome. Chest 1989; 96: 291S.
158. Smith EF III, Kinter LB, Jugus M, Wasserman MA, Eckardt RO, Newton JF. Beneficial effects of the peptidoleukotriene receptor antagonist, SK and F 104353, on the responses to experimental endotoxemia in the conscious rat. Circ Shock 1988; 25: 21-31.
159. Byrne K, Sielaff TD, Michna B et al. Increased survival time after delayed histamine and prostaglandin blockade in a porcine model of severe sepsis-induced lung injury. Crit Care Med 1990; 18: 303-8.
160. Turner CR, Quinlan MF, Schwartz LW, Wheeldon EB. Therapeutic intervention in a rat model of ARDS. I. Dual inhibition of arachidonic acid metabolism. Circ Shock 1990; 32: 231-42.
161. Dhainaut JF, Tenaillon A, Le Tulzo Y et al. Platelet-activating factor receptor antagonist BS 52021 in the treatment of severe sepsis: a randomized double-blind, placebo-controlled multicenter clinical trial. BN 52021 Sepsis Study Group. Crit Care Med 1994; 22: 1720-8.
162. Ridings PC, Blocher CR, Fisher BJ, Fowler AA III, Sugerman HJ. Beneficial effects of a bradykinin antagonist in a model of Gram-negative sepsis. J Trauma 1995; 39: 81-8.
163. Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med 1996; 24: 1125-8.
164. Bone RC. Immunologic dissonance: a continuing evolution in our understanding of the systemic inflammatory response syndrome (SIRS) and the multiple organ dysfunction syndrome (MODS). Ann Intern Med 1996; 125: 680-7.
165. Bone RC. Why sepsis trials fail. JAMA 1996; 276: 565-6.